AstraZeneca

Debate between Kit Malthouse and Chris Bryant
Monday 3rd February 2025

(1 month ago)

Commons Chamber
Read Full debate Read Hansard Text Read Debate Ministerial Extracts

Urgent Questions are proposed each morning by backbench MPs, and up to two may be selected each day by the Speaker. Chosen Urgent Questions are announced 30 minutes before Parliament sits each day.

Each Urgent Question requires a Government Minister to give a response on the debate topic.

This information is provided by Parallel Parliament and does not comprise part of the offical record

Chris Bryant Portrait Chris Bryant
- View Speech - Hansard - - - Excerpts

Regional mayors have an important role to play in helping bring investment into key areas. I am happy to ensure that the meetings that my hon. Friend has asked for take place. This has to be a joint venture between everyone. I want to underline that it is not the case that AstraZeneca is leaving the United Kingdom, or that it does not have confidence in the United Kingdom, because it clearly does—it invests more than £2.5 billion every year into the UK economy. It is a key partner of the UK and will continue to be so.

Kit Malthouse Portrait Kit Malthouse (North West Hampshire) (Con)
- View Speech - Hansard - -

What a shame the Minister has chosen to substitute aggression for what should be regret for what is, whichever way he paints it, obviously a terrible failure of negotiation. I chair the all-party parliamentary group for life sciences, and I can tell the House that this is a terrible blow not just for Speke and Liverpool—the city of my birth—but for our vaccination development environment generally. The lack of this production facility means that there will be no pull for vaccination development in the UK and the various technologies that come with it. What will he do to replace that?

Chris Bryant Portrait Chris Bryant
- View Speech - Hansard - - - Excerpts

Of course we feel regretful. We would have preferred to get this over the line but that was not possible, in large measure because AstraZeneca decided that it did not add up in whatever particular way for it. The right hon. Gentleman makes one very good point: we want a manufacturing provision in the country, and my colleague Lord Vallance is working on that very closely with the sector.